| Trial ID: | L6785 |
| Source ID: | NCT02365233
|
| Associated Drug: |
Dpp4 Inhibitor
|
| Title: |
Fatty Liver Study in Patients With Type II Diabetes
|
| Acronym: |
|
| Status: |
TERMINATED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT02365233/results
|
| Conditions: |
Type II Diabetes|Nonalcoholic Fatty Liver
|
| Interventions: |
DRUG: DPP4 inhibitor|DRUG: Pioglitazone|DRUG: Lantus insulin
|
| Outcome Measures: |
Primary: Change in Hepatic Lipid Content From Baseline Visit to Six Month Follow up Visit, Comparison of the hepatic lipid content measurement taken by MRI at baseline with the measurement taken by MRI at the 6 month follow up visit., Hepatic lipid content measurement will be taken on Day #1 ( the day of randomization) and at the 6 month follow up visit. |
|
| Sponsor/Collaborators: |
Sponsor: The University of Texas Medical Branch, Galveston
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
5
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2013-05-01
|
| Completion Date: |
2016-12-31
|
| Results First Posted: |
2018-07-31
|
| Last Update Posted: |
2018-07-31
|
| Locations: |
University of Texas Medical Branch -Galveston, Galveston, Texas, 77555, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT02365233
|
